Therapeutic potential of β-arrestin- and G protein-biased agonists.

Therapeutic potential of β-arrestin- and G protein-biased agonists.
复制标题

DOI:
10.1016/j.molmed.2010.11.004
复制
发表时间:
2011-03
影响因子:
13.6
通讯作者:
Lefkowitz RJ
Lefkowitz RJ
中科院分区:
医学1区
文献类型:
--
作者:
Whalen EJ;Rajagopal S;Lefkowitz RJ

文献摘要

参考文献

被引文献

相似文献

七跨膜受体(7 TMR)或G蛋白偶联受体(GPCR)超家族的成员代表了现代药物治疗的一些最成功的靶标,在治疗广泛的人类病症和疾病过程中具有已证实的功效。现在认识到,β-抑制蛋白曾经被简单地视为传统7 TMR刺激的G蛋白信号传导的负调节剂,其充当调节7 TMR脱敏和运输并以其自身的权利促进不同的细胞内信号的多功能衔接蛋白。此外,已经鉴定了几种7 TMR偏向激动剂,其选择性地激活这些不同的信号传导途径。在这里,我们强调了G蛋白和β-抑制蛋白介导的功能的多样性,以及在疾病状态下选择性靶向这些功能的治疗潜力。
Members of the seven-transmembrane receptor (7TMR), or G protein-coupled receptor (GPCR), superfamily represent some of the most successful targets of modern drug therapy, with proven efficacy in the treatment of a broad range of human conditions and disease processes. It is now appreciated that β-arrestins, once viewed simply as negative regulators of traditional 7TMR-stimulated G protein signaling, act as multifunctional adapter proteins that regulate 7TMR desensitization and trafficking and promote distinct intracellular signals in their own right. Moreover, several 7TMR biased agonists, which selectively activate these divergent signaling pathways, have been identified. Here we highlight the diversity of G protein- and β-arrestin-mediated functions and the therapeutic potential of selective targeting of these in disease states.
DOI: 10.1016/j.nbd.2004.10.005
发表时间: 2005-03-01
影响因子: 6.1
作者:
Bezard, E;Gross, CE;Gurevich, EV
通讯作者: Gurevich, EV
DOI: 10.1074/jbc.m202544200
发表时间: 2002-10-11
影响因子: 4.8
作者:
Bisello, A;Chorev, M;Ferrari, SL
通讯作者: Ferrari, SL
DOI: 10.1124/mol.54.1.94
发表时间: 1998-07-01
影响因子: 3.6
作者:
Berg, KA;Maayani, S;Clarke, WP
通讯作者: Clarke, WP
DOI: 10.1091/mbc.01-03-0129
发表时间: 2002-02-01
影响因子: 3.3
作者:
Blanpain, C;Vanderwinden, JM;Mack, M
通讯作者: Mack, M
DOI: 10.1210/en.139.7.3185
发表时间: 1998-07-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Bhowmick, N;Narayan, P;Puett, D
通讯作者: Puett, D